Currently out of the existing stock ratings of David Novak, 16 are a BUY (100%).

David Novak

Work Performance Price Targets & Ratings Chart

Analyst David Novak, currently employed at STIFEL, carries an average stock price target met ratio of 62.5% that have a potential upside of 60.31% achieved within 223 days. Previously, David Novak worked at RAYMOND JAMES.

David Novak’s has documented 30 price targets and ratings displayed on 6 stocks. The coverage is on the Healthcare sector.

Most recent stock forecast was given on ZYME, Zymeworks Common Stock at 10-Dec-2021.

Wall Street Analyst David Novak

Analyst best performing recommendations are on ZYME (ZYMEWORKS COMMON STOCK).
The best stock recommendation documented was for ZYME (ZYMEWORKS COMMON STOCK) at 10/1/2019. The price target of $40 was fulfilled within 52 days with a profit of $14.91 (59.43%) receiving and performance score of 11.43.

Average potential price target upside

of $276 (72.96%) on TCRT (ALAUNOS THERAPEUTICS).
of $14.24 (90.88%) on ZYME (ZYMEWORKS COMMON STOCK).
of $13.7 (77.4%) on LPTX (LEAP THERAPEUTICS).

CBIO Catalyst Biosciences ZYME Zymeworks Common Stock LPTX Leap Therapeutics TCRT Alaunos Therapeutics ZIOP ZIOPHARM Oncology MEDXF Medexus Pharmaceuticals

Show more stocks

Analyst name

Rating

Rating initiation date

Current price target

Potential Upside

Previous price target

Date

Price targets met ratio

Average potential upside

Average Days to Hit Target

Performance score